It’s only fair to share… Vaborbactam RN: 1360457-46-0 UNII: 1C75676F8V Molecular Formula. C12-H16-B-N-O5-S Molecular Weight. 297.1374 1,2-Oxaborinane-6-acetic acid, 2-hydroxy-3-((2-(2-thienyl)acetyl)amino)-, (3R,6S)- B1([C@H](CC[C@H](O1)CC(=O)O)NC(=O)Cc2cccs2)O RPX7009 A beta-lactamase inhibitor. Treatment of Bacterial Infection {(3R,6S)-2-Hydroxy-3-[(2-thienylacetyl)amino]-1,2-oxaborinan-6-yl}acetic acid 2-[(3R,6S)-2-hydroxy-3-[(2-thiophen-2-ylacetyl)amino]oxaborinan-6-yl]acetic acid 1,2-Oxaborinane-6-acetic acid, 2-hydroxy-3-[[2-(2-thienyl)acetyl]amino]-, (3R,6S)- Ваборбактам [Russian] فابورباكتام [Arabic] 法硼巴坦 [Chinese] Originator Rempex Pharmaceuticals Developer The Medicines Company; US Department of Health and Human Services Class Antibacterials; Pyrrolidines; Small molecules; Thienamycins Mechanism …
FDA approval brings first gene therapy to the United States
It’s only fair to share… FDA approval brings first gene therapy to the United States 08/30/2017 The U.S. Food and Drug Administration issued a historic action today making the first gene therapy available in the United States, ushering in a new approach to the treatment of cancer and other serious and life-threatening diseases The U.S. …
FDA approves Mylotarg (gemtuzumab ozogamicin) for treatment of acute myeloid leukemia
It’s only fair to share… FDA approves Mylotarg for treatment of acute myeloid leukemia 09/01/2017 The U.S. Food and Drug Administration today approved Mylotarg (gemtuzumab ozogamicin) for the treatment of adults with newly diagnosed acute myeloid leukemia whose tumors express the CD33 antigen (CD33-positive AML). The FDA also approved Mylotarg for the treatment of patients …
FDA approves new antibacterial drug Vabomere (meropenem, vaborbactam)
It’s only fair to share… Meropenem Beta-lactamase inhibitor vaborbactam FDA approves new antibacterial drug 08/29/2017 The U.S. Food and Drug Administration today approved Vabomere for adults with complicated urinary tract infections (cUTI), including a type of kidney infection, pyelonephritis, caused by specific bacteria. Vabomere is a drug containing meropenem, an antibacterial, and vaborbactam, which inhibits …
FDA approves first U.S. treatment benznidazole for Chagas disease
It’s only fair to share… FDA approves first U.S. treatment for Chagas disease 08/29/2017 The U.S. Food and Drug Administration today granted accelerated approval to benznidazole for use in children ages 2 to 12 years old with Chagas disease. It is the first treatment approved in the United States for the treatment of Chagas …
TOZADENANT
It’s only fair to share… Tozadenant RO-449351 SYN-115 Molecular Formula C19H26N4O4S Average mass 406.499 Da A2 (3); A2a-(3); RO4494351; RO4494351-000; RO4494351-002; SYN-115 Phase III clinical trials at Biotie Therapies for the treatment of Parkinson’s disease as an adjunctive therapy with levodopa 1-Piperidinecarboxamide, 4-hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl- 4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-1,3-benzothiazol-2-yl]-4-methyl-1-piperidinecarboxamide 4-Hydroxy-N-[4-methoxy-7-(4-morpholinyl)-2-benzothiazolyl]-4-methyl-1-piperidinecarboxamide 4-Hydroxy-4-methyl-piperidine-1-carboxylic acid(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide CAS 870070-55-6 Originator Roche Developer Acorda Therapeutics Class Amides; Antiparkinsonians; Benzothiazoles; Carboxylic acids; …
Lifetime achievement award, WHC17, in Hyderabad, Telangana, India 22 Aug 2017
It’s only fair to share… Lifetime achievement award ……..WORLD HEALTH CONGRESS 2017 in Hyderabad, 22 aug 2017 at JNTUH KUKATPALLY. HYDERABAD, TELANGANA, INDIA, Award given by Dr. M Sunitha Reddy Head of the Department, Centre for Pharmaceutical Sciences, Institute of Science &Technology, JNTU-H, Kukatpally, Hyderabad, India Speaking at World health congress 2017….JNTUH Hyderabad 22 aug …
Prexasertib , прексасертиб , بريكساسيرتيب , 普瑞色替 ,
It’s only fair to share… Prexasertib Captisol® enabled prexasertib; CHK1 Inhibitor II; LY 2606368; LY2606368 MsOH H2O 5-(5-(2-(3-aminopropoxy)-6-methoxyphenyl)-1H-pyrazol-3-ylamino)pyrazine-2-carbonitrile 2-Pyrazinecarbonitrile, 5-[[5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl]amino]- Name Prexasertib Lab Codes LY-2606368 Chemical Name 5-({5-[2-(3-aminopropoxy)-6-methoxyphenyl]-1H-pyrazol-3-yl}amino)pyrazine-2-carbonitrile Chemical Structure Molecular Formula C18H19N7O2 UNII UNII:820NH671E6 Cas Registry Number 1234015-52-1 OTHER NAMES прексасертиб [Russian] [INN] بريكساسيرتيب [Arabic] [INN] 普瑞色替 [Chinese] [INN] Originator Array BioPharma Developer Eli Lilly, National Cancer Institute Mechanism Of Action …
RAPASTINEL рапастинел , راباستينيل , 雷帕替奈
It’s only fair to share… RAPASTINEL Molecular Formula C18H31N5O6 Average mass 413.469 Da L-threonyl-L-prolyl-L-prolyl-L-threoninamide (2S)-1-[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide 117928-94-6 [RN] L-Threoninamide, L-threonyl-L-prolyl-L-prolyl- рапастинел [Russian] راباستينيل [Arabic] 雷帕替奈 [Chinese] (S)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-((S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide UNII-6A1X56B95E; 117928-94-6; 6A1X56B95E (S)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-((S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide [117928-94-6] GLYX-13 trifluoroacetate GLYX-13;GLYX13;GLYX 13;Thr-Pro-Pro-Thr-NH2 L-Threonyl-L-prolyl-L-prolyl-L-threoninamide trifluoroacetate MFCD20527320 Thr-Pro-Pro-Thr-NH2 trifluoroacetate TPPT-amide trifluoroacetate UNII:6A1X56B95E BV-102; GLYX13, GLYX-13, in phase 3 clinical trials Originator Northwestern University Developer Allergan; Naurex Class Amides; Antidepressants; Neuropsychotherapeutics; Oligopeptides; Small molecules Mechanism of …
ICH Q11 Q and A Document
It’s only fair to share… ICH Q11 Q and A Document The topic of starting materials has been a vexed topic for some period. Indeed concerns relating to lack of clarity and issues pertaining to practical implementation led the EMA in Sept 2014 to publish a reflection paper—Reflection on the requirements for selection and …